DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



The Effect of Rosuvastatin on Adenosine Metabolism

Information source: Radboud University
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Adenosine Metabolism

Intervention: placebo (Drug); rosuvastatin (Drug)

Phase: N/A

Status: Completed

Sponsored by: Radboud University

Official(s) and/or principal investigator(s):
Gerard Rongen, MD, PhD, Study Director, Affiliation: Radboud University Medical Centre Dep. Pharmacology-Toxicology

Summary

The aim of this study is to show whether rosuvastatin influences adenosine metabolism. Therefore we will determine whether rosuvasatin increases dipyridamole-induced vasodilation by increased adenosine receptor stimulation.

Clinical Details

Official title: Rosuvastatin Augments Dipyridamole Induced Vasodilation by Increased Adenosine Receptor Stimulation.

Study design: Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science

Primary outcome: forearm vasodilatory response to dipyridamole

Secondary outcome: lipid profile

Eligibility

Minimum age: 18 Years. Maximum age: 50 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- age 18 - 50 years

- Signed informed consent

Exclusion Criteria:

- hypertension

- hypercholesterolemia

- diabetes Mellitus

- alanine aminotransferase > 90 U/L

- creatinine Kinase > 440 U/L

- cardiovascular disease

- GFR < 80 ml/min

Locations and Contacts

Radboud University Nijmegen Medical Centre, Nijmegen 6500 HB, Netherlands
Additional Information

Starting date: November 2007
Last updated: September 22, 2008

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017